Tobias Skillbäck1,2, Niklas Mattsson3,4, Kaj Blennow1,2, Henrik Zetterberg1,2,5. 1. a Institute of Neuroscience and Physiology, Department of Neurochemistry , The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden. 2. b Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , Mölndal , Sweden. 3. c Clinical Memory Research Unit, Department of Clinical Sciences Malmö , Lund University , Malmö , Sweden. 4. d Department of Neurology , Skåne University Hospital , Lund , Sweden , and. 5. e Department of Molecular Neuroscience , UCL Institute of Neurology, Queen Square , London , UK.
Abstract
OBJECTIVE: To aid diagnostics, patient stratification and studies seeking to find treatments for the related diseases motor neuron disease (MND) and frontotemporal dementia (FTD), there is a need to establish a way to assess disease severity and the amount of ongoing neurodegeneration. Previous studies have suggested that cerebrospinal fluid (CSF) neurofilament light (NFL) may serve this purpose. METHODS: We cross-referenced the Swedish mortality registry with the laboratory database at Sahlgrenska University Hospital to produce a dataset of CSF NFL concentrations and mortality information for 715 MND patients, 87 FTD patients, and 107 healthy controls. Biomarker concentrations were analysed in relation to recorded cause of death and time of death. RESULTS: MND patients had significantly higher CSF NFL concentrations than FTD patients. Both groups had significantly higher concentrations than the healthy controls (mean 709% increase in MND and 307% increase in FTD). Higher concentrations of CSF NFL were associated with shorter survival in both MND and FTD. CONCLUSIONS: The results of this study strengthen the notion of CSF NFL as a useful tool for determining disease intensity in MND and FTD patients. Further studies in patient cohorts with clinically subtyped and genetically classified diagnoses are needed.
OBJECTIVE: To aid diagnostics, patient stratification and studies seeking to find treatments for the related diseases motor neuron disease (MND) and frontotemporal dementia (FTD), there is a need to establish a way to assess disease severity and the amount of ongoing neurodegeneration. Previous studies have suggested that cerebrospinal fluid (CSF) neurofilament light (NFL) may serve this purpose. METHODS: We cross-referenced the Swedish mortality registry with the laboratory database at Sahlgrenska University Hospital to produce a dataset of CSF NFL concentrations and mortality information for 715 MND patients, 87 FTDpatients, and 107 healthy controls. Biomarker concentrations were analysed in relation to recorded cause of death and time of death. RESULTS: MND patients had significantly higher CSF NFL concentrations than FTDpatients. Both groups had significantly higher concentrations than the healthy controls (mean 709% increase in MND and 307% increase in FTD). Higher concentrations of CSF NFL were associated with shorter survival in both MND and FTD. CONCLUSIONS: The results of this study strengthen the notion of CSF NFL as a useful tool for determining disease intensity in MND and FTDpatients. Further studies in patient cohorts with clinically subtyped and genetically classified diagnoses are needed.
Entities:
Keywords:
Biomarkers in CSF; amyotrophic lateral sclerosis; frontotemporal dementia; motor neuron disease; neurofilament light protein
Authors: Bob Olsson; Erik Portelius; Nicholas C Cullen; Åsa Sandelius; Henrik Zetterberg; Ulf Andreasson; Kina Höglund; David J Irwin; Murray Grossman; Daniel Weintraub; Alice Chen-Plotkin; David Wolk; Leo McCluskey; Lauren Elman; Leslie M Shaw; Jon B Toledo; Jennifer McBride; Pilar Hernandez-Con; Virginia M-Y Lee; John Q Trojanowski; Kaj Blennow Journal: JAMA Neurol Date: 2019-03-01 Impact factor: 18.302
Authors: Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton Journal: Alzheimers Dement Date: 2020-01-06 Impact factor: 21.566
Authors: Michelle M Mielke; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Prashanthi Vemuri; Mary M Machulda; Jonathan Graff-Radford; David S Knopman; Clifford R Jack; Ronald C Petersen; Silke Kern Journal: Alzheimers Dement Date: 2019-10-23 Impact factor: 21.566
Authors: Jared S Katzeff; Fiona Bright; Katherine Phan; Jillian J Kril; Lars M Ittner; Michael Kassiou; John R Hodges; Olivier Piguet; Matthew C Kiernan; Glenda M Halliday; Woojin Scott Kim Journal: Brain Date: 2022-06-03 Impact factor: 15.255
Authors: Lieke H H Meeter; Everard G Vijverberg; Marta Del Campo; Annemieke J M Rozemuller; Laura Donker Kaat; Frank Jan de Jong; Wiesje M van der Flier; Charlotte E Teunissen; John C van Swieten; Yolande A L Pijnenburg Journal: Neurology Date: 2018-03-07 Impact factor: 9.910
Authors: Claudia Duran-Aniotz; Paulina Orellana; Tomas Leon Rodriguez; Fernando Henriquez; Victoria Cabello; María F Aguirre-Pinto; Tamara Escobedo; Leonel T Takada; Stefanie D Pina-Escudero; Oscar Lopez; Jennifer S Yokoyama; Agustin Ibanez; Mario A Parra; Andrea Slachevsky Journal: Front Neurol Date: 2021-06-24 Impact factor: 4.003